Table 2 Overview of numbers and shares of patients who were tested borderline (bdl.) or positive (pos.) for one or both anti-SARS-CoV-2 antibody (ab) classes within the whole cohort and in distinct subpopulations.
IgA bdl | IgA pos | IgA bdl./pos | IgG bdl | IgG pos | IgG bdl./pos | Any ab bdl./pos | |
|---|---|---|---|---|---|---|---|
All patients | 16 (4.6%) | 263 (75.8%) | 279 (80.4%) | 17 (4.9%) | 194 (55.9%) | 211 (60.8%) | 282 (81.3%) |
Male | 8 (3.9%) | 159 (78.3%) | 167 (82.3%) | 14 (6.9%) | 116 (57.1%) | 130 (64%) | 168 (82.8%) |
Female | 8 (5.6%) | 104 (72.2%) | 112 (77.8%) | 3 (2.1%) | 78 (54.2%) | 81 (56.3%) | 114 (79.2%) |
ICU | 0 | 51 (94.4%) | 51 (94.4%) | 2 (3.7%) | 43 (79.6%) | 45 (83.3%) | 51 (94.4%) |
Deceased | 0 | 25 (65.8%) | 25 (65.8 5) | 2 (5.3%) | 18 (47.4%) | 20 (52.6%) | 26 (68.4%) |
